EPISCREEN

Serial Number 86716415
Registration 5093688
704

Registration Progress

Application Filed
Aug 6, 2015
Under Examination
Aug 23, 2016
Approved for Publication
Jun 28, 2016
Published for Opposition
Jun 28, 2016
Registered
Dec 6, 2016

Attorney Assistance

Section 8 & 9 Renewal Due (Principal Register) (Based on registration date 20161206)
Due: Dec 06, 2026 307 days

Trademark Image

EPISCREEN

Basic Information

Serial Number
86716415
Registration Number
5093688
Filing Date
August 6, 2015
Registration Date
December 6, 2016
Published for Opposition
June 28, 2016
Drawing Code
4

Status Summary

Current Status
Active
Status Code
704
Status Date
Sep 30, 2023
Registration
Registered
Classes
005 042 044

Rights Holder

ABZENA (UK) LIMITED

24
Address
900 BABRAHAM RESEARCH CAMPUS, BABRAHAM
CAMBRIDGE CB22 3AT
GB

Ownership History

Polytherics Limited

Original Applicant
11
Cambridge GB

Polytherics Limited

Owner at Publication
11
Cambridge GB

Polytherics Limited

Original Registrant
11
Cambridge GB

ABZENA (UK) LIMITED

New Owner After Registration #1
24
CAMBRIDGE GB

Legal Representation

Attorney
Joyce von Natzmer

USPTO Deadlines

Next Deadline
307 days remaining
Section 8 & 9 Renewal Due (Principal Register) (Based on registration date 20161206)
Due Date
December 06, 2026
Grace Period Ends
June 06, 2027

Application History

30 events
Date Code Type Description Documents
Dec 6, 2025 REM2 E COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED Loading...
Sep 30, 2023 NAS8 E NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED Loading...
Sep 30, 2023 8.PR O REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED Loading...
Sep 22, 2023 EROP I TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED Loading...
Jun 2, 2023 PRA8 O POST REGISTRATION ACTION MAILED - SEC. 8 Loading...
Jun 2, 2023 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Dec 2, 2022 ES8R I TEAS SECTION 8 RECEIVED Loading...
Dec 6, 2021 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jul 31, 2019 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Dec 6, 2016 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Oct 31, 2016 DP1B I 1(B) BASIS DELETED; PROCEED TO REGISTRATION Loading...
Oct 11, 2016 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
Oct 30, 2016 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Oct 11, 2016 EPPA I TEAS POST PUBLICATION AMENDMENT RECEIVED Loading...
Aug 23, 2016 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 28, 2016 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 28, 2016 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 8, 2016 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 20, 2016 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
May 13, 2016 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 5, 2016 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
May 5, 2016 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 28, 2016 ALIE A ASSIGNED TO LIE Loading...
Apr 15, 2016 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Nov 19, 2015 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 19, 2015 GNRT F NON-FINAL ACTION E-MAILED Loading...
Nov 19, 2015 CNRT R NON-FINAL ACTION WRITTEN Loading...
Nov 18, 2015 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 11, 2015 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 10, 2015 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
[ Pharmaceuticals and pharmaceutical preparations used to treat cancer, diseases and disorders of the immune system, viral diseases and disorders, inflammatory diseases, fibrotic diseases, pulmonary diseases, gastro-intestinal diseases and disorders, haematological diseases and disorders, neurological diseases and disorders, pain, obesity, diabetes and graft rejection; chemical preparations for medical or pharmaceutical purposes, namely, chemicals sold as integral component parts of pharmaceutical preparations for the treatment of cancer, diseases and disorders of the immune system, viral diseases and disorders, inflammatory diseases, fibrotic diseases, pulmonary diseases, gastro-intestinal diseases and disorders, haematological diseases and disorders, neurological diseases and disorders, pain, obesity, diabetes and graft rejection; chemico-pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer, diseases and disorders of the immune system, viral diseases and disorders, inflammatory diseases, fibrotic diseases, pulmonary diseases, gastro-intestinal diseases and disorders, haematological diseases and disorders, neurological diseases and disorders, pain, obesity, diabetes and graft rejection; vaccines; pharmaceutical preparations for skin care ]
Class 042
Scientific research and product development services in relation to pharmaceutical and medical products; pharmaceutical research services; pharmaceutical product evaluation; testing of pharmaceuticals, namely, assessing the potential immunogenicity of proteins and antibodies by measuring immune cell responses to the pharmaceutical; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of scientific information in the fields of cancer, diseases and disorders of the immune system, viral diseases and disorders, inflammatory diseases, fibrotic diseases, pulmonary diseases, gastro-intestinal diseases and disorders, haematological diseases and disorders, neurological diseases and disorders, pain, obesity, diabetes and graft rejection; toxicology services; provision of scientific information relating to the chemical industry, namely, information on the subject of chemical product development
Class 044
Medical services, namely, providing medical information regarding pharmaceuticals; Pharmacy and health advice; pharmaceutical services and provision of pharmaceutical information, all in the nature of providing medical information regarding pharmaceuticals; Medical screening; Medical screening to assess the potential immunogenicity of therapeutic antibodies and proteins

Classification

International Classes
005 042 044